StemCell Therapy

World Longevity Economy Size Projections, current USD

AI for Longevity has more potential to increase healthy Longevity in the short term than any other sector. The application of AI for Longevity will bring the greatest real-world benefits and will be the main driver of progress in the widespread extension of healthy Longevity. The global spending power of people aged 60 and over is anticipated to reach $15 trillion annually by 2020. The Longevity industry will dwarf all other industries in both size and market capitalization, reshape the globalfinancial system, and disrupt the business modelsof pension funds, insurance companies, investment banks, and entire national economies.

Longevity has become a recurring topic in analytical reports from leading financial institutions such as CitiBank, UBS Group, Julius Baer, and Barclays. At the recent AI for Longevity Summit in London, top executives from Prudential, HSBC, AXA Insurance, NVIDIA, Microsoft, Babylon Health, Insilico Medicine, Longevity.Capital, Longevity Vision Fund, Juvenescence, Deep Knowledge Ventures, and the UK All-Party Parliamentary Group for Longevity came together to discuss the Longevity Industry. International policymakers and senior corporate executives shared learnings from Japan, Israel, Switzerland, the US, and the UK and exchanged ideas on beginning to work together in a new social contract to enhance global prosperity equitably.

The 7th Continent - 1 Billion People in Retirement Globally

Switzerland is one of the most longevity progressive countries in the world with both high investment in biotechnology and the capacity to integrate AI into its economic, financial, and healthcare systems. Switzerland has the potential to be a world leader in both the Global Longevity Industry and the 4th Industrial Revolution. There are currently 100 companies, 80 investors, 50 financial companies, 35 research labs, 20 precision medicine clinics, 15 nonprofits, and 10 governmental organizations in the Swiss Longevity Industry. Switzerland is in an excellent position to retain its leading position by focusing on the optimal assembly of its existing resources to transform the challenge of demographic aging into a national asset.

Switzerland has a large aging population and Swiss investment banks are acutely aware of the oncoming demographic challenge. Switzerland is one of the most efficiently regulated and supervised financial centers in the world and has been leading transformative developments emerging from the digitalization of its banking and financial sector. Longevity-progressive countries typically have large aging populations, and aging populations have two longevity-progressive benefits: voting power and spending power.

Longevity Industry in Switzerland 2019

The digitization of finance, and novel financial systems which treat Longevity as a dividend, will play an integral role in the Longevity economy. According to a recent report by Aging Analytics Agency, Switzerland has the elements necessary to become a leading Longevity financial hub, including factors such as a lean political system that facilitates rapid implementation of integrated government programs, a strong research environment for geroscience, a strong research and business environment for digital health, and most importantly, international financial prowess.

Switzerland has the ability to develop several Longevity specific programs over the next several years. One program is a Longevity progressive pension system and insurance company ecosystem that accounts for both population aging (which threatens to destabilize the current business models of insurance companies and pension funds) and the potential for widespread healthspan extension. Another program is a national strategy for intensively developing Geroscience and FinTech to a state so advanced that it propels Switzerland into a central role in the international Longevity business ecosystem and a global leader in Longevity Finance. Switzerland is leading the digitization of financial markets and establishing itself as a catalyst for financial innovation on a global level. According to Aging Analytics Agency, 10% of all European FinTech enterprises are located in Switzerland.

Switzerland has a strong and productive geroscience community and has gained prominence among investors as a global biotech hub and hotbed of innovation. The Swiss Institute for Bioinformatics has recently identified large numbers of genetic markers directly linked to human life expectancy. Switzerland is also home to the prestigious Vontobel Prize for Aging Research.

The Convergence of 5 Mega Trends

BioValley

Switzerland is situated at one end of the BioValley - one of the leading life science clusters in Europe. This cluster is unique in that it spans across three countries, Switzerland, Germany and France, and includes Basel, a global life science hub. BioValley brings together important ingredients for a successful biotech cluster including a concentration of companies, rich availability of skills, experience within Life Sciences, and a world class research base. The cluster in Switzerland has in excess of 50,000 people working in the life sciences field including 15,000 scientists. There are 600 companies in the cluster developing therapeutic, diagnostic or medical devices to address a wide range of diseases in multiple therapeutic classes. There are 100,000 students enrolled in 10 universities and research institutions including University of Basel, Max Planck Institute, and Freiburg University. The cluster has produced a number of spin-out companies supported by a financial network including both public and private financing initiatives as well as traditional venture capital and private equity. The entire process of drug development is covered in the region, from research through to clinical and drug development, and manufacturing.

Longevity AI Consortium Expands to Switzerland

Longevity AI Consortium King's College London

In November 2019, Europes firstLongevity AI Consortium(LAIC)launched at King's College London. LAIC is currently developing collaborative research projects withDynamics of Healthy Ageing (DynAge)and theDigital Society Initiative (DSI)at the University of Zurich. The research will utilize AI technologies to predict the future cognitive ability of individuals using multimodal neuroimaging and risk factor data. Academics in Zurich will work in collaboration with colleagues at the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. LAIC plans to establish several collaborative projects with the University of Zurich in 2020. The joint R&D between Ageing Research at Kings and University of Zurich forms the first phase of the global Longevity AI Consortium that will eventually be extended to Israel, Singapore, Japan and the US.

The Longevity Industry

AgeTech

FinTech banks are redefining the banking industry by connecting with a new generation of mobile-first consumers. However, FinTech banks are focusing on consumers who are middle-age and younger, not on the 1 billion people in retirement and the $15 trillion dollar market opportunity. As the share of the population over 60 increases, Swiss banks are lagging behind in finding solutions for this age group. Traditional banks, as opposed to challenger banks, are making their first steps in AgeTech, adapting their infrastructure for people over 60.

WealthTech

The WealthTech Industry refers to a new generation of financial technology companies that create digital solutions to transform the investment and asset management industry. New companies have arrived on the scene offering advice based on AI and big data, micro-investment platforms, and trading solutions based on social networks. A growing aging population is one of the main drivers of innovation in WealthTech. Financial services innovators have an opportunity to enhance the financial lives of individuals over 60 by designing new solutions and adapting existing products and services for them. This is an opportunity to implement innovations that address financial health challenges head on.

Financial Wellness

As a core component of its mission to develop Switzerland into a leading international Longevity Financial Industry hub, Longevity Swiss Foundation plans on roadmapping the development of AI Centers for Financial Wellness. Whereas the proposed AI Centers for Longevity would focus on optimizing health, these centers would focus on the application of AI to the creation of methods and technologies to promote wellness in other areas including financial wellness, continuing education, psychological well being, neuroplasticity, and active social involvement. The planned development of AI Centers for Financial Wellness will enable financial stability over extended periods of healthy Longevity for Swiss citizens.

Switzerland could become the center of the Longevity Financial Industry. Given its geographic size and its reliance on international cooperation, its function in the Longevity Industry will be as a small but important node. Due to its status as an international BioTech epicenter and its reputation as one of the most progressive countries in terms of its financial industry, the prospects for Switzerland to lead the world in the development of its Longevity Financial Industry are strong.

Today, change occurs at the intersection of two or more scientific and technological domains. We are at the beginning of a trend where the degree of complexity and the number of convergence points will increase exponentially. The convergence of AI, advanced data science, and Longevity research will accelerate important medical breakthroughs that will benefit all humans. In the next decade, the Longevity Industry will impact many areas of our lives. Longevity policies enacted by governments and changes in the global financial industry will transform society. Achieving small but practical results in Longevity distributed at scale will have enormous and multiplicative effects on society. Extending the functional lifespan of humans by just one year will decrease suffering for tens of millions of people and will improve the quality of life for billions of people.

See the original post here:
AI Will Drive The Multi-Trillion Dollar Longevity Economy - Forbes

In a recent study undertaken by scientists from the National Institutes of Health and National Institute of Aging, researchers found the secret to longevity is linked with meal times.

The researchers separated 292 male mice into two groups and gave them different diets. They also examined how altering the meal times affected the life expectancy of the mice. At the end of the study period, the scientists found the results to be very impressive and concluded that the same might be true for humans. happy man longevity Photo: rottonara - Pixabay

They said the findings provided a beacon of hope for future studies and at the same time, suggested a particular diet to help improve longevity. This study, which was participated in part by scientists from the Pennington Biomedical Research Centre and the University of Wisconsin-Madison, analyzed how longer fasting times could boost health and longevity. Researchers noted that increasing the time between meals improved the overall health of the male mice. They also lived longer compared to the other group who were fed and ate more frequently.

The scientists also report that health and life span greatly improved with increased fasting times, notwithstanding the type of food the mice ate or how many calories the food contained.Dr. Richard J. Hodes, a director at the NIA, said that the study revealed that the group of mice that consumed only one meal daily appears to enjoy a longer lifespan. They also seem to have better outcomes for age-related ailments like liver disease and a number of metabolic disorders.

He also said that the fascinating results using lab mice as the model which revealed the relationship of fasting and feeding time length and total caloric intake deserve a closer examination.

Dr. Rafael de Cabo, the studys lead author and Translational Gerontology Branch chief of the NIA Intramural Research Program, said increasing daily fasting times improved the overall health of male mice. He also said that their survival chances in a number of age-related ailments also increased. These positive results occurred regardless of the caloric intake and the type of diet the mice have.

The lead author hypothesized that the extended fasting period might have enabled the maintenance and repair mechanisms of the mices bodies to kick into place. Such a process would have been absent had the mice ate food continuously.Researchers of the study also revealed the results seem to suggest that those who are able to fast at least once a month may enjoy a longer and healthier life.

View original post here:
You Can Improve Longevity By Having This Diet At Least Once A Month - International Business Times

Courtesy South Shore YMCA Ruth Kundsin, 103, works out with her personal trainer Dick Raymond at the South Shore YMCA in Quincy, Massachusetts.

People lifting weights at a gym in suburban Boston can be forgiven if they have no clue the energetic woman working out next to them is 103 years old.

Ruth Kundsins exercise routine includes cardio and strength training, a lifestyle thats more active now than the decades she spent working as a microbiologist only reluctantly retiring in her 80s.

She still lives on her own, loves parties and works out with a personal trainer every Friday at the South Shore YMCA in Quincy, Massachusetts.

I feel better afterwards and I think its keeping me vertical, Kundsin told TODAY, expressing surprise at all the excitement about her centenarian status.

Its really funny to me. I think Ive gotten more accolades for my age than I have for my science and thats sort of strange because you have nothing to do with your age. I mean, you just age, but the science I really worked hard on.

Dick Raymond, who has been her personal trainer for 10 years, said weights are the most important part of her routine.

We work every part of her body trying to keep her strong, Raymond, 69, noted. The older you get, the more you need exercise because you lose strength as you age. You can prevent that you can get better at any age.

Heres what Kundsin attributes to her longevity:

Kundsin described herself as having a very upbeat, optimistic, happy outlook on life. If something disturbs her, she gets over it, she said.

Its very important to have something to look forward to. If you dont have anything to look forward to, life is bleak and dull. But it seems like I always have something to look forward to and if there isnt anything, I make it, like I throw a party, Kundsin said.

I know that no matter how bad I feel, in a little while, Ill be feeling pretty good. I dont really worry about anything any great length of time.

The daughter of Latvian immigrants, Kundsin received a doctorate of science from Harvard School of Public Health in 1958.

Kundsin felt passionate about her work as a scientist and insisted on working even though it upset her family at a time when women were expected to stay home with their children.

She was the first mother to work in her community, facing intense scrutiny from her neighbors. Even Kundsins husband didnt want her to work, but she got her own way.

Thank goodness. Now I know it was the right thing to do, she said. Its a satisfaction to have a job I loved my work.

Kundsin had 150 papers published in scientific journals and wrote five books. She worked as an associate professor at Harvard Medical School until she was 81.

Scientific work is sedentary, so after spending much of her life bent over a microscope, Kundsin decided she had to make up for it when she retired.

When an acquaintance invited her to come to a gym, she thought it would be fun and has been exercising regularly ever since. She particularly liked swimming, taking part in Senior Games and competing at the national level three times.

She started working out with Raymond at age 93. The personal trainer focuses on having her do exercises that are challenging for her because challenging things are what improve you. Easy things dont improve you, he said.

Besides her weekly workouts, Kundsin cooks for herself and takes care of her house, doing chores and climbing up and down stairs, which Dick approves of, she said.

Kundsin isnt the first centenarian Raymond has worked with. He at one point also trained his father, who recently passed away at 101.

Unlike many centenarians TODAY has profiled, Kundsin smoked cigarettes for many years and didnt quit until her 70s. Still, she hasnt had any major health problems like cancer or heart disease, she said. Its only within the past year that shes started using a cane because of balance issues.

Kundsin doesnt eat beef, but otherwise does nothing special when it comes to her diet.

Influenced by Raymonds advice, she now eats oatmeal topped with lots of fruit for breakfast and has started avoiding sugar after a lifetime of eating desserts.

She drinks a glass of wine every night not because she loves it but because she believes its good for health. Indeed, research of people who lived to 90 and beyond found those who drank moderate amounts of alcohol lived longer than those who abstained.

I should be drinking red wine, but I think its a little strong for me so I drink white wine. I prefer champagne, Kundsin said.

Related Video: 104-Year-Old Runner Shares Her Longevity Tips (Provided by Today)

UP NEXT

View original post here:
103-year-old shares secrets to longevity: Exercise and wine - msnNOW

The secret to long life expectancy is to follow a healthy lifestyle - regularly exercising, limiting alcohol intake, not smoking and eating a healthy balanced diet. When it comes to eating a healthy diet, the NHS recommends eating at least five portions of a variety of fruit and vegetables every day, basing meals on higher fibre starchy foods like potatoes, bread, rice or pasta, having some dairy or dairy alternatives, some protein, choosing unsaturated oils and spreads, and eating them in small amounts, and drinking plenty of fluids. A new study also suggests a different approach to meal times and how it could impact on your health.

In the study with the National Institute of Ageing (NIA) and the National Institutes of Health, longer daily fasting times and how it could improve health and longevity was analysed. The study noted: Increasing time between meals made male mice healthier overall and live longer compared to mice who at more frequently. Scientists from the University of Wisconsin-Madison and the Pennington Biomedical Research Centre, Baton Rouge, Louisiana , reports that health and longevity improved with increased fasting time, regardless of what the mice ate or how many calories they consumed. https://www.sciencedaily.com/releases/2018/09/180906123305.htm

DONT MISS

NIA director, Dr Richard J. Hodes said: This study showed that mice who ate one meal per day and thus had the longest fasting period, seemed to have a longer lifespan and better outcomes for common age-related liver disease and metabolic disorders.

"These intriguing results in an animal model show that the interplay of total caloric intake and the length of feeding and fasting periods deserves a closer look.

See original here:
How to live longer: Following this diet once a month could increase your life expectancy - Express

Visit the News Hub

Long life study explores genetics of extreme longevity

A new grant from the National Institute on Aging of the National Institutes of Health (NIH) supports research into the mysteries of extreme longevity. Researchers at Washington University School of Medicine in St. Louis are leading the Long Life Family Study, which includes several generations of families with unusual concentrations of long-lived individuals. The goal is to uncover genetic factors that play roles in long life spans.

Washington University School of Medicine in St. Louis has received a $68 million grant to investigate and discover what contributes to extreme longevity. The researchers are studying hundreds of families over several generations with individuals who have had exceptionally long lives. Many of these families have unusual concentrations of people living to at least age 100.

The goal of the Long Life Family Study, funded by the National Institute on Aging of the National Institutes of Health (NIH), is to identify genetic factors that contribute to exceptional longevity. Such information could lead to new therapeutics or other health innovations to help people live longer, healthier lives.

These families provide a unique opportunity for finding genetic links to long life spans, said principal investigator Michael A. Province, PhD, a Washington University professor of genetics. Remarkably, many study participants in the older generations are unusually healthy for their ages. We think we will find clues in their DNA that suggest how they might be protected from common diseases, such as diabetes or Alzheimers disease or, at the very least, uncover genetic factors that might delay the onset of these health problems.

The School of Medicine is the coordinating center for the project, which has field centers at Boston University, Columbia University, the University of Pittsburgh and the University of Southern Denmark. Province and Mary K. Wojczynski, PhD, an assistant professor of genetics at Washington University, lead the primary site and coordinate collaborations among the field sites and the University of Minnesota, where the laboratory for analyzing blood samples is located.

The study includes almost 5,000 individuals from three generations of 539 families across the United States and Denmark, first recruited from 2006 through 2009. The average age of representatives of the oldest generation in the study was 90 at that time, with some individuals exceeding 110. Those in the second generation of these families now average over 70 years of age, and the grandchildren of the oldest group are now in their 50s, on average. Studying multiple generations of families with histories of long lives presents the opportunity to study individuals who have a greater chance of reaching older ages. In particular, it provides the ability to study such individuals when they are younger and not yet obviously different from those with shorter life spans.

When we study long-lived people, we would really like to be able to travel back in time and study them before they reach older ages to see how they might differ from the general population when those differences might not yet be obvious, Province said. Our earlier findings from this study have shown that individuals in the second generation are healthier, on average, than individuals from families with more typical longevity, when measured, for example, in middle age. But these healthier traits vary by family. For example, some long-lived families might tend to have lower blood pressure while others might have better cognition into later life, and still others might have better lung function or grip strength. Across these families, there is no single factor that stands out as the main reason for the long health and life spans.

The researchers suspect this variability may be linked to specific rare genetic variants that may protect such families from the harmful effects of aging in a variety of ways. The new funding will support whole genome sequencing of study participants in an effort to identify special protective variations in the DNA.

The researchers also will study the consequences of such differences in DNA through analyzing what effects they might have on the proteins, metabolites and other molecules that have a direct impact on the bodys biology. Such measures change with age, and the researchers are interested in comparing these with more average populations over their life spans. The comparison group is composed of participants from the well-known Framingham Heart Study, which has been tracking the health of multiple generations of families living in Framingham, Mass., since that study began in 1948. The researchers said less than 1% of families participating in the Framingham Heart Study meet the longevity criteria of the Long Life Family Study.

One genetic characteristic that stands out in some but not all long-lived families is the length of telomeres, or the end caps on chromosomes that protect the DNA from damage. Every time a cell divides, the telomeres get a little shorter, and shorter telomeres have been associated with chronic diseases, such as diabetes, heart disease, dementia and other disorders common among elderly people. Long-lived families seem to have longer than average telomeres.

Telomere length might be one key component of healthy aging, Province said. There is evidence that healthy behaviors like exercise can protect telomere length or even extend it. But there is a genetic component to it as well. Some people just naturally have longer telomeres, or at least appear to have resilient telomeres. And that is the case in many of the families were studying. Based on that data, we have honed in on a gene that could be involved in telomere length, and this new grant will help us explore that possibility and other new avenues further.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

View post:
Families with long, healthy life spans focus of $68 million grant - Washington University School of Medicine in St. Louis

Washington (AFP)

In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering -- by editing her genome.

Victoria Gray's recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research -- gene therapy.

"I have hoped for a cure since I was about 11," the 34-year-old told AFP in an email.

"Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency."

Over several weeks, Gray's blood was drawn so doctors could get to the cause of her illness -- stem cells from her bone marrow that were making deformed red blood cells.

The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 -- pronounced "Crisper" -- a new tool informally known as molecular "scissors."

The genetically edited cells were transfused back into Gray's veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary but, theoretically, she has been cured.

"This is one patient. This is early results. We need to see how it works out in other patients," said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.

"But these results are really exciting."

In Germany, a 19-year-old woman was treated with a similar method for a different blood disease, beta thalassemia. She had previously needed 16 blood transfusions per year.

Nine months later, she is completely free of that burden.

For decades, the DNA of living organisms such as corn and salmon has been modified.

But Crispr, invented in 2012, made gene editing more widely accessible. It is much simpler than preceding technology, cheaper and easy to use in small labs.

The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.

"It's all developing very quickly," said French geneticist Emmanuelle Charpentier, one of Crispr's inventors and the cofounder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

- Cures -

Crispr is the latest breakthrough in a year of great strides in gene therapy, a medical adventure started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.

Scientists practising the technique insert a normal gene into cells containing a defective gene.

It does the work the original could not -- such as making normal red blood cells, in Victoria's case, or making tumor-killing super white blood cells for a cancer patient.

Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.

They join several other gene therapies -- bringing the total to eight -- approved in recent years to treat certain cancers and an inherited blindness.

Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.

"Twenty-five, 30 years, that's the time it had to take," he told AFP from Paris.

"It took a generation for gene therapy to become a reality. Now, it's only going to go faster."

Just outside Washington, at the National Institutes of Health (NIH), researchers are also celebrating a "breakthrough period."

"We have hit an inflection point," said Carrie Wolinetz, NIH's associate director for science policy.

These therapies are exorbitantly expensive, however, costing up to $2 million -- meaning patients face grueling negotiations with their insurance companies.

They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion -- and fighting a general infection.

"You cannot do this in a community hospital close to home," said her doctor.

However, the number of approved gene therapies will increase to about 40 by 2022, according to MIT researchers.

They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

- Bioterrorism -

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who don't necessarily share the medical ethics of Western medicine.

Last year in China, scientist He Jiankui triggered an international scandal -- and his excommunication from the scientific community -- when he used Crispr to create what he called the first gene-edited humans.

The biophysicist said he had altered the DNA of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV, even though there was no specific reason to put them through the process.

"That technology is not safe," said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr "scissors" often cut next to the targeted gene, causing unexpected mutations.

"It's very easy to do if you don't care about the consequences," Musunuru added.

Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.

There is also the temptation to genetically edit entire animal species -- malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.

The researchers in charge of those projects are advancing carefully, however, fully aware of the unpredictability of chain reactions on the ecosystem.

Charpentier doesn't believe in the more dystopian scenarios predicted for gene therapy, including American "biohackers" injecting themselves with Crispr technology bought online.

"Not everyone is a biologist or scientist," she said.

And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies' crops?

Charpentier thinks that technology generally tends to be used for the better.

"I'm a bacteriologist -- we've been talking about bioterrorism for years," she said. "Nothing has ever happened."

2019 AFP

Read more:
2019: the year gene therapy came of age - RFI

NEW YORK, Dec. 2, 2019 /PRNewswire/ --

Nerve Repair and Regeneration market worldwide is projected to grow by US$7.3 Billion, driven by a compounded growth of 12.6%. Biomaterials, one of the segments analyzed and sized in this study, displays the potential to grow at over 11.6%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$3.1 Billion by the year 2025, Biomaterials will bring in healthy gains adding significant momentum to global growth.

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=PRN

- Representing the developed world, the United States will maintain a 11.3% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$288.1 Million to the region's size and clout in the next 5 to 6 years. Over US$242.9 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Biomaterials will reach a market size of US$112 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16% over the next couple of years and add approximately US$1.7 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include, among others, Abbott Laboratories; Baxter International, Inc.; Boston Scientific Corporation; Integra LifeSciences Holdings Corporation; LivaNova PLC; Medtronic PLC; NeuroPace, Inc.; Nevro Corp.; Nuvectra Corporation; Orthomed; Polyganics BV; Stryker Corporation

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=PRN

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Neuroregeneration - A Prelude Rise in Aging Population, and High Incidence of Neurological Disorders Drive the Global Nerve Repair and Regeneration Market Neurostimulation and Neuromodulation Devices- Largest Segment Biomaterials to Grow at a Faster Rate Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Nerve Connectors Technological Advancements and Product Innovations - A Key Growth Driver Innovation in Deep Brain Stimulation for Parkinson?s Disease Innovations in Spinal Cord Stimulation for Pain Global Competitor Market Shares Nerve Repair and Regeneration Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: Nerve Repair and Regeneration Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 2: Nerve Repair and Regeneration Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 Table 3: Nerve Repair and Regeneration Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Biomaterials (Product) World Market by Region/Country in US$ Million: 2018 to 2025 Table 5: Biomaterials (Product) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 6: Biomaterials (Product) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Neurostimulation and Modulation Devices (Product) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 8: Neurostimulation and Modulation Devices (Product) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 9: Neurostimulation and Modulation Devices (Product) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Neurorrhaphy (Application) Global Market Estimates & Forecasts in US$ Million by Region/Country: 2018-2025 Table 11: Neurorrhaphy (Application) Retrospective Demand Analysis in US$ Million by Region/Country: 2009-2017 Table 12: Neurorrhaphy (Application) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 13: Nerve Grafting (Application) Demand Potential Worldwide in US$ Million by Region/Country: 2018-2025 Table 14: Nerve Grafting (Application) Historic Sales Analysis in US$ Million by Region/Country: 2009-2017 Table 15: Nerve Grafting (Application) Share Breakdown Review by Region/Country: 2009 VS 2019 VS 2025 Table 16: Stem Cell Therapy (Application) Worldwide Latent Demand Forecasts in US$ Million by Region/Country: 2018-2025 Table 17: Stem Cell Therapy (Application) Global Historic Analysis in US$ Million by Region/Country: 2009-2017 Table 18: Stem Cell Therapy (Application) Distribution of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 19: Neurostimulation Surgery (Application) Sales Estimates and Forecasts in US$ Million by Region/Country for the Years 2018 through 2025 Table 20: Neurostimulation Surgery (Application) Analysis of Historic Sales in US$ Million by Region/Country for the Years 2009 to 2017 Table 21: Neurostimulation Surgery (Application) Global Market Share Distribution by Region/Country for 2009, 2019, and 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Nerve Repair and Regeneration Market Share (in %) by Company: 2019 & 2025 Table 22: United States Nerve Repair and Regeneration Market Estimates and Projections in US$ Million by Product: 2018 to 2025 Table 23: Nerve Repair and Regeneration Market in the United States by Product: A Historic Review in US$ Million for 2009-2017 Table 24: United States Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 25: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Million by Application: 2018 to 2025 Table 26: Nerve Repair and Regeneration Historic Demand Patterns in the United States by Application in US$ Million for 2009-2017 Table 27: Nerve Repair and Regeneration Market Share Breakdown in the United States by Application: 2009 VS 2019 VS 2025 CANADA Table 28: Canadian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018 to 2025 Table 29: Canadian Nerve Repair and Regeneration Historic Market Review by Product in US$ Million: 2009-2017 Table 30: Nerve Repair and Regeneration Market in Canada: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 31: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Million by Application: 2018 to 2025 Table 32: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Million by Application for 2009-2017 Table 33: Canadian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 JAPAN Table 34: Japanese Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Million by Product for the Period 2018-2025 Table 35: Nerve Repair and Regeneration Market in Japan: Historic Sales Analysis in US$ Million by Product for the Period 2009-2017 Table 36: Japanese Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 37: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 38: Japanese Nerve Repair and Regeneration Market in US$ Million by Application: 2009-2017 Table 39: Nerve Repair and Regeneration Market Share Shift in Japan by Application: 2009 VS 2019 VS 2025 CHINA Table 40: Chinese Nerve Repair and Regeneration Market Growth Prospects in US$ Million by Product for the Period 2018-2025 Table 41: Nerve Repair and Regeneration Historic Market Analysis in China in US$ Million by Product: 2009-2017 Table 42: Chinese Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 43: Chinese Demand for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 44: Nerve Repair and Regeneration Market Review in China in US$ Million by Application: 2009-2017 Table 45: Chinese Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 EUROPE Market Facts & Figures European Nerve Repair and Regeneration Market: Competitor Market Share Scenario (in %) for 2019 & 2025 Table 46: European Nerve Repair and Regeneration Market Demand Scenario in US$ Million by Region/Country: 2018-2025 Table 47: Nerve Repair and Regeneration Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 Table 48: European Nerve Repair and Regeneration Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 49: European Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018-2025 Table 50: Nerve Repair and Regeneration Market in Europe in US$ Million by Product: A Historic Review for the Period 2009-2017 Table 51: European Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 52: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Million by Application: 2018-2025 Table 53: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Million by Application for the Period 2009-2017 Table 54: European Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 FRANCE Table 55: Nerve Repair and Regeneration Market in France by Product: Estimates and Projections in US$ Million for the Period 2018-2025 Table 56: French Nerve Repair and Regeneration Historic Market Scenario in US$ Million by Product: 2009-2017 Table 57: French Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 58: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Million by Application: 2018-2025 Table 59: French Nerve Repair and Regeneration Historic Market Review in US$ Million by Application: 2009-2017 Table 60: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 GERMANY Table 61: Nerve Repair and Regeneration Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 62: German Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 63: German Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 64: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Million by Application for the Period 2018-2025 Table 65: German Nerve Repair and Regeneration Market in Retrospect in US$ Million by Application: 2009-2017 Table 66: Nerve Repair and Regeneration Market Share Distribution in Germany by Application: 2009 VS 2019 VS 2025 ITALY Table 67: Italian Nerve Repair and Regeneration Market Growth Prospects in US$ Million by Product for the Period 2018-2025 Table 68: Nerve Repair and Regeneration Historic Market Analysis in Italy in US$ Million by Product: 2009-2017 Table 69: Italian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 70: Italian Demand for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 71: Nerve Repair and Regeneration Market Review in Italy in US$ Million by Application: 2009-2017 Table 72: Italian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 UNITED KINGDOM Table 73: United Kingdom Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Million by Product for the Period 2018-2025 Table 74: Nerve Repair and Regeneration Market in the United Kingdom: Historic Sales Analysis in US$ Million by Product for the Period 2009-2017 Table 75: United Kingdom Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 76: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 77: United Kingdom Nerve Repair and Regeneration Market in US$ Million by Application: 2009-2017 Table 78: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by Application: 2009 VS 2019 VS 2025 SPAIN Table 79: Spanish Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018 to 2025 Table 80: Spanish Nerve Repair and Regeneration Historic Market Review by Product in US$ Million: 2009-2017 Table 81: Nerve Repair and Regeneration Market in Spain: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 82: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Million by Application: 2018 to 2025 Table 83: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Million by Application for 2009-2017 Table 84: Spanish Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 RUSSIA Table 85: Russian Nerve Repair and Regeneration Market Estimates and Projections in US$ Million by Product: 2018 to 2025 Table 86: Nerve Repair and Regeneration Market in Russia by Product: A Historic Review in US$ Million for 2009-2017 Table 87: Russian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 88: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Million by Application: 2018 to 2025 Table 89: Nerve Repair and Regeneration Historic Demand Patterns in Russia by Application in US$ Million for 2009-2017 Table 90: Nerve Repair and Regeneration Market Share Breakdown in Russia by Application: 2009 VS 2019 VS 2025 REST OF EUROPE Table 91: Rest of Europe Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018-2025 Table 92: Nerve Repair and Regeneration Market in Rest of Europe in US$ Million by Product: A Historic Review for the Period 2009-2017 Table 93: Rest of Europe Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 94: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Million by Application: 2018-2025 Table 95: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Million by Application for the Period 2009-2017 Table 96: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 ASIA-PACIFIC Table 97: Asia-Pacific Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 98: Nerve Repair and Regeneration Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 Table 99: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 100: Nerve Repair and Regeneration Market in Asia-Pacific by Product: Estimates and Projections in US$ Million for the Period 2018-2025 Table 101: Asia-Pacific Nerve Repair and Regeneration Historic Market Scenario in US$ Million by Product: 2009-2017 Table 102: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 103: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Million by Application: 2018-2025 Table 104: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Million by Application: 2009-2017 Table 105: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 AUSTRALIA Table 106: Nerve Repair and Regeneration Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 107: Australian Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 108: Australian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 109: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Million by Application for the Period 2018-2025 Table 110: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Million by Application: 2009-2017 Table 111: Nerve Repair and Regeneration Market Share Distribution in Australia by Application: 2009 VS 2019 VS 2025 INDIA Table 112: Indian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018 to 2025 Table 113: Indian Nerve Repair and Regeneration Historic Market Review by Product in US$ Million: 2009-2017 Table 114: Nerve Repair and Regeneration Market in India: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 115: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Million by Application: 2018 to 2025 Table 116: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Million by Application for 2009-2017 Table 117: Indian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 SOUTH KOREA Table 118: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 119: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 120: Nerve Repair and Regeneration Market Share Distribution in South Korea by Product: 2009 VS 2019 VS 2025 Table 121: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Application for the Period 2018-2025 Table 122: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Application: 2009-2017 Table 123: Nerve Repair and Regeneration Market Share Distribution in South Korea by Application: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 124: Rest of Asia-Pacific Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Million by Product for the Period 2018-2025 Table 125: Nerve Repair and Regeneration Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Product for the Period 2009-2017 Table 126: Rest of Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 127: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 128: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Million by Application: 2009-2017 Table 129: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by Application: 2009 VS 2019 VS 2025 LATIN AMERICA Table 130: Latin American Nerve Repair and Regeneration Market Trends by Region/Country in US$ Million: 2018-2025 Table 131: Nerve Repair and Regeneration Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 Table 132: Latin American Nerve Repair and Regeneration Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 133: Latin American Nerve Repair and Regeneration Market Growth Prospects in US$ Million by Product for the Period 2018-2025 Table 134: Nerve Repair and Regeneration Historic Market Analysis in Latin America in US$ Million by Product: 2009-2017 Table 135: Latin American Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 136: Latin American Demand for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 137: Nerve Repair and Regeneration Market Review in Latin America in US$ Million by Application: 2009-2017 Table 138: Latin American Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 ARGENTINA Table 139: Argentinean Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018-2025 Table 140: Nerve Repair and Regeneration Market in Argentina in US$ Million by Product: A Historic Review for the Period 2009-2017 Table 141: Argentinean Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 142: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Million by Application: 2018-2025 Table 143: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Million by Application for the Period 2009-2017 Table 144: Argentinean Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 BRAZIL Table 145: Nerve Repair and Regeneration Market in Brazil by Product: Estimates and Projections in US$ Million for the Period 2018-2025 Table 146: Brazilian Nerve Repair and Regeneration Historic Market Scenario in US$ Million by Product: 2009-2017 Table 147: Brazilian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 148: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Million by Application: 2018-2025 Table 149: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Million by Application: 2009-2017 Table 150: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 MEXICO Table 151: Nerve Repair and Regeneration Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 152: Mexican Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 153: Mexican Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 154: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Million by Application for the Period 2018-2025 Table 155: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Million by Application: 2009-2017 Table 156: Nerve Repair and Regeneration Market Share Distribution in Mexico by Application: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 157: Rest of Latin America Nerve Repair and Regeneration Market Estimates and Projections in US$ Million by Product: 2018 to 2025 Table 158: Nerve Repair and Regeneration Market in Rest of Latin America by Product: A Historic Review in US$ Million for 2009-2017 Table 159: Rest of Latin America Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 160: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Million by Application: 2018 to 2025 Table 161: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by Application in US$ Million for 2009-2017 Table 162: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by Application: 2009 VS 2019 VS 2025 MIDDLE EAST Table 163: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 164: Nerve Repair and Regeneration Market in the Middle East by Region/Country in US$ Million: 2009-2017 Table 165: The Middle East Nerve Repair and Regeneration Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 166: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018 to 2025 Table 167: The Middle East Nerve Repair and Regeneration Historic Market by Product in US$ Million: 2009-2017 Table 168: Nerve Repair and Regeneration Market in the Middle East: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 169: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Million by Application: 2018 to 2025 Table 170: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Million by Application for 2009-2017 Table 171: The Middle East Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 IRAN Table 172: Iranian Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Million by Product for the Period 2018-2025 Table 173: Nerve Repair and Regeneration Market in Iran: Historic Sales Analysis in US$ Million by Product for the Period 2009-2017 Table 174: Iranian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 175: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 176: Iranian Nerve Repair and Regeneration Market in US$ Million by Application: 2009-2017 Table 177: Nerve Repair and Regeneration Market Share Shift in Iran by Application: 2009 VS 2019 VS 2025 ISRAEL Table 178: Israeli Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Million by Product: 2018-2025 Table 179: Nerve Repair and Regeneration Market in Israel in US$ Million by Product: A Historic Review for the Period 2009-2017 Table 180: Israeli Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 181: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Million by Application: 2018-2025 Table 182: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Million by Application for the Period 2009-2017 Table 183: Israeli Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 184: Saudi Arabian Nerve Repair and Regeneration Market Growth Prospects in US$ Million by Product for the Period 2018-2025 Table 185: Nerve Repair and Regeneration Historic Market Analysis in Saudi Arabia in US$ Million by Product: 2009-2017 Table 186: Saudi Arabian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 187: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Million by Application: 2018 to 2025 Table 188: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Million by Application: 2009-2017 Table 189: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 UNITED ARAB EMIRATES Table 190: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 191: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 192: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Product: 2009 VS 2019 VS 2025 Table 193: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Application for the Period 2018-2025 Table 194: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Application: 2009-2017 Table 195: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Application: 2009 VS 2019 VS 2025 REST OF MIDDLE EAST Table 196: Nerve Repair and Regeneration Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Product for the Period 2018-2025 Table 197: Rest of Middle East Nerve Repair and Regeneration Historic Market Analysis in US$ Million by Product: 2009-2017 Table 198: Rest of Middle East Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 199: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Million by Application for the Period 2018-2025 Table 200: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Million by Application: 2009-2017 Table 201: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by Application: 2009 VS 2019 VS 2025 AFRICA Table 202: African Nerve Repair and Regeneration Market Estimates and Projections in US$ Million by Product: 2018 to 2025 Table 203: Nerve Repair and Regeneration Market in Africa by Product: A Historic Review in US$ Million for 2009-2017 Table 204: African Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 205: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Million by Application: 2018 to 2025 Table 206: Nerve Repair and Regeneration Historic Demand Patterns in Africa by Application in US$ Million for 2009-2017 Table 207: Nerve Repair and Regeneration Market Share Breakdown in Africa by Application: 2009 VS 2019 VS 2025

IV. COMPETITION

ABBOTT LABORATORIES BAXTER INTERNATIONAL BOSTON SCIENTIFIC CORPORATION INTEGRA LIFESCIENCES HOLDINGS CORPORATION LIVANOVA PLC MEDTRONIC PLC NEUROPACE NEVRO CORP. NUVECTRA CORPORATION ORTHOMED POLYGANICS BV STRYKER CORPORATION

V. CURATED RESEARCHRead the full report: https://www.reportlinker.com/p05799212/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

See the rest here:
Global Nerve Repair and Regeneration Industry - PRNewswire

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report 2018-2026includes a comprehensive analysis of the present Market. The report starts with the basic Autologous Stem Cell and Non-Stem Cell Based Therapies industry overview and then goes into each and every detail.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Autologous Stem Cell and Non-Stem Cell Based Therapies also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.

Description:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market competition by top manufacturers/players, with Autologous Stem Cell and Non-Stem Cell Based Therapies sales volume, Price (USD/Unit), Revenue (Million USD) and Market Share for each manufacturer/player; the top players including: NeoStem, Inc., Aastrom Biosciences, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.

Get Free Sample Copy Of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/523

Important Features that are under offer & key highlights of the report:

What all regional segmentation covered? Can the specific country of interest be added?Currently, the research report gives special attention and focus on the following regions:North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

What all companies are currently profiled in the report?The report Contain the Major Key Players currently profiled in this market.** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

Can we add or profiled new company as per our need?Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by the research team depending upon the difficulty of the survey.** Data availability will be confirmed by research in case of a privately held company. Up to 3 players can be added at no added cost.

Can the inclusion of additional Segmentation / Market breakdown is possible?Yes, the inclusion of additional segmentation / Market breakdown is possible to subject to data availability and difficulty of the survey. However, a detailed requirement needs to be shared with our research before giving final confirmation to the client.** Depending upon the requirement the deliverable time and quote will vary.

Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/523

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Dynamics in the world mainly, the worldwide 2018-2026 Autologous Stem Cell and Non-Stem Cell Based Therapies Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Region Segmentation:

North America (USA, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Columbia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Further in the report, the Autologous Stem Cell and Non-Stem Cell Based Therapies market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and region is also included. The Autologous Stem Cell and Non-Stem Cell Based Therapies industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

Quick Buy This Premium Report From Here: https://www.coherentmarketinsights.com/insight/buy-now/523

In this study, the years considered to estimate the market size of 2018-2026 Autologous Stem Cell and Non-Stem Cell Based Therapies Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2026

The rest is here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Growth and Demand Analysis By Global Top Key Players Like and Others 2018-2026 - The...

DUBLIN, Dec. 6, 2019 /PRNewswire/ -- The "The State of Personalized/ Precision Medicine" report has been added to ResearchAndMarkets.com's offering.

This report covers current and future challenges for the development and launch of these medicines, focusing on challenges with transitioning these therapies from bench to bedside and demonstrating efficacy in order to secure reimbursement.

Report ScopeDefinition of Personalized/Precision Medicine - Key attributes of personalized/precision medicine, examining and contrasting definitions by regulatory bodies and KOL respondents.

Personalized Medicine-Impact on Healthcare - Key factors to impacting healthcare for patients and stakeholders providing respondent mix by region and organization size.

Marketed Products - Detailed information is provided for key personalized/precision medicines, including case studies for marketed oncology and rare disease therapeutics.

Pipeline Products - The diverse Phase III pipeline is presented, including detailed information on key candidate's mechanism of action and clinical trial parameters.

Investment in Personalized Medicine - Investment in personalized medicine by indication and clinical trial design and approaches are presented, with case studies for three ongoing oncology trials being considered.

Market Opportunities and Challenges - Key areas of opportunity and roadblocks in developing, launching, and gaining reimbursement are analyzed by geography, company size, and seniority level.

Emerging Trends - Critical new trends, including the use of advanced digital technologies, are examined.Key Topics Covered

1. Preface

2. Executive Summary

3. Overview of Personalized/Precision Medicine3.1 Definition3.2 Definition of Personalized/Precision Medicine3.3 KOL and Payer Perspecive3.4 Key Attributes of Personalized Medicine Therapy3.5 Types of Biomarkers and Diagnostics

4. Impact of Personalized Medicine on Healthcare4.1 Personalized Medicine - Impact on Healthcare - Patients4.2 Advantages of Personalized Medicine - Patients4.3 Role of Personalized Medicine in Clinical Unmet Needs4.4 Personalized Medicine - Impact on Healthcare - Drug Developers' Perspective4.5 Advantages of Personalized Medicine to Drug Developers4.6 Personalized Medicine - Impact on Healthcare - Health System

5. Key Marketed Products

6. Pipeline Products

7. Investment in Personalized Medicine

8. Deal-Making Landscape

9. Market Opportunities and Challenges

10. Pricing, Reimbursement, and Regulatory Strategy

11. Personalized Medicine - Emerging Trends

12. Summary of Key Findings

13. Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/v886fo

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/the-state-of-personalizedprecision-medicine-in-2019-impact-on-healthcare-marketed-products-pipeline-products-investments-market-opportunities--challenges-emerging-trends-300970564.html

SOURCE Research and Markets

Read the rest here:
The State of Personalized/Precision Medicine in 2019: Impact on Healthcare, Marketed Products, Pipeline Products, Investments, Market Opportunities &...

Ritu Jha-

Prasun Mishra, founding President and CEO of the American Association for Precision Medicine (AAPM) says the demise of his elder sister to pancreatic cancer led him to this work to create awareness about precision (or personalized) medicine.

It was a kind of a calling for me, Mishra told indica at the AAPM annual meeting 2019 held this past month at the Santa Clara Convention Center. Initially I was very sad for my personal loss but eventually I realized it was not just me. Everybody is facing the same thing and has the same story and I am just one of them.

The daylong meeting was based on the theme Accelerating Precision Medicine and Transforming Patient Health. It was attended by both national and international professors, experts, and thought leaders in the fields of precision medicine, life science, biotech, MedTech and pharma.

Mishra, a serial entrepreneur is the Founder and CEO of Agility Pharmaceuticals, founded by AAPM in 2017 with a mission to save lives by accelerating the field of precision medicine through research, education, communication, and collaboration.

Mishra says it was not easy to build a precision medicine community and there was no non-profit voice before them. There were for profit activists out there but the real community message is hard to create. It was also hard to have a meaningful dialogue about precision medicine to create resources and funds.

In our community we have medical doctors, pharma executives, investors, entrepreneurs, and scientists and are pulling our heads together to solve the toughest problem, he added.

A lot of work was done in the previous decade in the field of precision medicine at the universities, even pharma companies and precision medicine come under health care but it is still in the burgeoning stage.

When asked if lifestyle is a part of precision medicine, Mishra said, It includes lifestyle and yes, lifestyle plays a big role. We are monitoring the patients health and behavior [to see] how it impacts their life [] and trying to see how we could through technology and resources predict, based on lifestyle what outcome [the patient] would have.

When asked about President Barack Obamas launch of the Precision Medicine Initiative in 2015 and the $215 million investment in the Presidents 2016 Budget Mishra gave the example said even private companies like Verily, a Google company, they are working on it and have been profiling patients lifestyle, including sleep pattern and genomics data. They have recently acquired Fitbit for $2.1 billion.

So the question is what led to the awareness of precision medicine? Technology or the growing Cancer killer disease? Mishra believes its both. Its a combination and of course there is frustration for not able to make a difference in the life of loved ones and that is the main cause.

During his presentation, Mishra also highlighted another move by Google that might help boost this growing demand, said, I think Google Quantum computers will be very good [at performing] certain tasks in the future and Quantum computers is much needed as it works much faster than regular computers.

But there are challenges, when it comes to data, Mishra stated that the problem is there are a lot of manual facts in the healthcare system and its on paper in the medical records.

Now we are trying to work together as a community and as a consortium on how can we solve that issue. So that manual data needs to be digitized or you can say the whole health care system needs big a U-Haul, and there are many hurdles and we have to move forward and solve each one at a time.

There are many hurdles still. We have a lot of unstructured data and we need defined data sets. We have to make an innovation to collect that data, Mishra said.

When asked if there is awareness of personalized medicine among the South Asian community, he said that precision medicines goal is to define the community, whether its the Indian or American community.

Based on how you respond to disease we are prone to certain things and diet and our lifestyle, and it would be good to have a community to have genomics data, some companies are working on but still we be are far behind in terms of collecting massive data. In India certain organizations are working. We could come together as a community.

Adding further he said as a community [coming] together would generate a pool of data and would help [figure out] what kind of medicine would respond to them.

Precision medicine is also about growing people, individual groups of ethnicity, community and similar genetic group and then treating and doing research. What are the common genetic factors that are missing and gained and use that knowledge to deliver the promise of precision medicine, said Mishra and added that the next 10 years, are going to be very exciting.

I have predicted that in 5 years and as technology is moving forward exponentially we could do so many things and with AI intervention, we could even detect diabetic retinopathy, Radiology, Mishra said and that would even help rural areas where there are no physicians.

The future is very bright and as a community, if we are passionate about making a difference, we will make the progress that is needed in 10 years or earlier.

Another speaker at the conference Pritmohinder Gill, PhD, Associate Professor at the Arkansas Childrens Research Institute, UAMS said the demand grew because of the growing cancer.

Cancer is the area where more therapeutic value from precision medicine has gone. It is the main beneficiary because we are able to target those particular genes in a particular individual, said Professor Gill.

But he sees a long way to go as its expansive and needs more research and both medicine and technology are very expensive.

He said a single medicine could cost $3000 per sample. Some companies commercialize and can do that for 1500 dollars and many places of academia has fewer resources and infrastructure to support new AI-based technology.

UAMS has no money, and without the growth of technology and AI and if you dont have support its very hard to say which gene is impacting you and your condition. Certainly many of the psychiatric disorders are multi-gene.

Without research, there is no understanding of what is happening. The key is research and only after research, you can take these findings to that side.

Pointing to the recent drugs approved by the FDA he said that in 2018, 42 percent of drugs approved by the FDA were personalized medicine drugs.

When asked how to reduce the cost, Professor Gill said that in Norway they have a population of 6 million and all the inhabitants in Norway have their whole genome sequencing done.

The UK is planning now and its in their database and physicians can access it for writing a prescription.

Thats basically where healthcare will move.

But Prof. Gill believes it would take 50 years because its all money and needs regulation and it depends on how the FDA is doing.

Meanwhile, Dr. Sanjeev Jain, CEO of The Columbia Asthma & Allergy Clinic who spoke at the panel, Role of Physicians Transforming Precision Health says precision is useful in helping to customize the treatment plan for each individual when doing allergy immune therapy.

He said he had lots of data but not enough resources, so he is looking forward to collaborating with Stanford University to build a joint database.

Currently the database is going to be focused on food allergies. Hopefully in future we can do it for other diseases, said Dr. Jain.

View post:
Is Precision Medicine the Future of Healthcare? - indica News

December 06, 2019 -In recent years, genomics and genetic data have emerged as an innovative area of research that could potentially transform healthcare. This information could accelerate precision medicine, paving the way for individualized therapies tailored to each person.

Studies have examined how genomics could improve care for Alzheimers, heart failure, and a number of other diseases, leading to a more personalized standard of treatment.

However, this new source of information could also come with unprecedented challenges. Organizations will need new ways of storing this data, and providers and patients will need to be prepared to handle the answers genomic information could hold.

What are some of the benefits of using genomics in healthcare, and how can the industry overcome the possible challenges that can accompany this information?

Proactive, not reactive, care delivery

READ MORE: Big Data Analytics, Precision Medicine Top Priorities in 2020

Using genomic data, providers can identify patients who are at high risk of developing certain conditions and better plan for treatments. This approach could be particularly helpful in proactively treating cognitive or behavioral disorders before people show signs of disease.

Recently, researchers from The Hospital for Sick Children (SickKids) and the University of Alberta found that testing the DNA of siblings of individuals with autism spectrum disorder (ASD) may be predictive of a future diagnosis even if symptoms arent yet apparent.

Genetic factors are the most likely reason we see a clustering of ASD related traits in families, said Dr. Stephen Scherer, Senior Scientist and Director of The Centre for Applied Genomics (TCAG) at SickKids, Director of the McLaughlin Centre at the University of Toronto and principal investigator of the study.

We wanted to investigate the possible benefits of genetic testing for infants whose older sibling had already been diagnosed with ASD. If we can identify those children early, we may be able to enroll them earlier in therapies.

In a separate study published in the American Journal of Psychiatry, a team from the University of North Carolina (UNC) at Chapel Hill used polygenic risk scores (PRS) based on genome-wide association studies to improve psychosis risk prediction in patients meeting high-risk criteria.

READ MORE: How Real-World Data Could Advance Clinical Trials, Precision Medicine

Previous studies reported the PRS discriminates persons with established schizophrenia from unaffected persons. Our study is the first to indicate the PRS predicts future psychosis suggesting a PRS may facilitate the development and eventual targeting of preemptive interventions, said Diana O. Perkins, MD, MPH, a professor of psychiatry in the UNC School of Medicine.

Individualized care that goes beyond the individual

One of the most exciting benefits of genomics and precision medicine is the promise of therapies that are tailored to meet each patients specific needs. Providers can access an individuals genetic code and better determine what sort of treatment is right for him or her, leading to better outcomes and lower costs.

However, genomics also has the potential to improve treatment beyond the level of the individual, boosting health and well-being for entire patient populations.

If the population health community and the precision medicine community would talk to each other more, I suspect they would find that they have a great deal in common, Jonathan Sheldon, former Global Vice President of Healthcare at Oracle Health Sciences, said in a 2017 interview with HealthITAnalytics.com.

READ MORE: How Precision Medicine Could Boost Chronic Disease Management

Precision medicine gives us the molecular tools to phenotype diseases, which you can then predict and manage at the population level.Genomics gives you that level of precision that is often lacking in risk stratification algorithms.They really enhance one another.Theyre not competitive in any way.

Healthcare organizations have recognized the complementary nature of genomics and population health management. In March 2018, the Healthy Nevada Project, a population health study combining genomic data with socioeconomic, environmental, and clinical information, entered its second collection phase.

The project aims to gather insights about how lifestyle interacts with genetics, improving population health for people in Nevada and around the world.

Genomics could also help researchers and providers uncover why particular conditions impact certain races or ethnicities more than others. A recent study published in the journal Nature showed that a genetic mutation linked to blood sugar levels occurs in one percent of Hispanic/Latino people and about six percent of African Americans, but very rare in people of European descent.

Our study confirmed that the apparent effects of the same genetic variant often vary across populations,saidSteve Buyske, a senior author and an associate professor in theDepartment of Statisticsat RutgersNew Brunswick. A genetic variant with a big effect in people of European descent may have a smaller effect in other populations, and vice versa.

These findings could help advance precision medicine treatments for entire populations, many of which may be underrepresented in studies and clinical trials.

More data, more problems

Although genomics and genetic data could give providers a more comprehensive picture of patient health, the industry still has significant data challenges to overcome before this information can be used at the point of care.

A March 2018 survey from Oracle and GenomeWeb showed that data management and storage were ranked among the top obstacles organizations currently face when trying to achieve their precision medicine goals.

Additionally, many survey participants who said they had no plans to pursue a precision medicine initiative cited insufficient technical infrastructure as their most significant barrier. Health systems will need to implement innovative data storage and management tools to realize the benefits of precision medicine and genomics.

The science is changing rapidly every day. Today, there are literally thousands of variants of unknown significance in every patient, and tomorrow some of those variants will be associated with a syndrome, Joel Diamond, MD, adjunct associate professor of biomedical informatics at the University of Pittsburgh, told HealthITAnalytics.com.

The industry needs an enterprise technology solution that can keep up with new advancements, as well as recognize when changes occur in a patient's clinical condition.

Diamond said that organizations should adopt system-wide standards and strategies that make genomics part of a comprehensive solution, as well as adopt advanced technologies like FHIR.

Even without genetic data standards, organizations should have a genetic data strategy in place, said Diamond.Instead of storing this data in PDFs, genetic information can be stored in various files that the organization has right now, in a standard way that allows the data to be usable down the line.

Patient, provider education

As advanced genetic testing becomes more affordable and accessible, more people will be looking to better understand their health risks. While this could help accelerate precision medicine, providers will need to be sure theyre ready to discuss the results of these tests with their patients.

In 2017, Wamberg Genomic Advisors showed that 16 percent of patients are confused by their genetic testing results, and an additional six percent experienced mild depression or anxiety after reviewing their personal data.

Providers, on their part, may not feel totally prepared to talk with their patients about these results. A recent survey of 130 primary care physicians showed that just 23 percent said they would feel comfortable discussing genetics as a risk factor for common diseases.

Geisinger Health System has recently integrated genomics with routine clinical care, and the organization has made patient and provider education a top priority.

One of the challenges we've tried to address up front is the education aspect what the results mean, both on the patient side and the clinician side, she said.

We've developed what we call Just in Time documents that doctors can give to their patients, which say, This is the information that we learned about you. This is what you need to do now given this information. This is what you need to monitor over time, and this is what you need to do long term. Anticipating the needs of patients and providers as they get this new type of information is important.

While there are challenges to leveraging genomics and genetics in healthcare, the potential benefits the information could provide outweigh the barriers. With innovative data storage tools and strategies to educate patients and providers about this new data, health systems could accelerate precision medicine and personalized treatments.

Continue reading here:
Evaluating the Benefits and Challenges of Genomics in Healthcare - HealthITAnalytics.com

Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies can position themselves as leaders at the forefront of these exciting innovations.

Personalised and precision medicines represent an evolution in healthcare, in which traditional clinical information and new data points including genetic data, and healthcare technology come together to match the right patient with the right treatment at the right time.

In short, it means moving away from the one-size-fits-all approach, in which many patients are treated with the same therapy, to targeted treatments that are often based on the patients DNA and the DNA of their disease.

In November 2019, Blue Latitude Health sponsored the 15th Annual Personalized Medicine Conference hosted by thePersonalized Medicine Coalition. Healthcare professionals, patients, payers, providers and pharmaceutical executives joined together to discuss the challenges and opportunities for those operating in this space.

Here, we deep dive into five of the key trends discussed to explore how the healthcare industry is changing and how pharmaceutical and biotech companies can position themselves as leaders at the forefront of innovation.

Download the article to uncover our analysis of the following trends, including real-life case studies:

* Innovative pricing models in precision and personalised healthcare

* Novel approaches in tracking patient data in the long term

* The importance of taking an individualised approach to clinical trials

* A new regulatory landscape for laboratory-developed tests

* Why the behaviour of healthcare professionals will need to change in this new era.

DOWNLOAD THE FULL ARTICLE HERE

Link:
Five key trends in precision and personalised healthcare - PMLiVE

MINNEAPOLIS, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.(POAI) (Predictive Oncology or the Company), focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced that it has received indications of interest from several parties for the possible acquisition of its Skyline Medical division, which produces and sells the STREAMWAY System for disposal of fluids in medical applications. As previously announced, Predictive Oncology has determined that it will focus its resources on its primary mission of applying artificial intelligence to precision medicine and drug discovery.

Skyline Medicals patented, FDA-approved STREAMWAY System is the first truly continuous, direct-to-drain fluid disposal system designed specifically for medical applications. The division has expanded sales globally and made significant inroads in U.S. markets.

Dr. Carl Schwartz, Predictive Oncologys Chief Executive Officer commented, I am exceptionally pleased with the rapid growth and development of our Helomics and Tumor Genesis divisions, as well as the multiple indications of interest for our Skyline Medical division. If this results in the sale of Skyline Medical, it would not only provide additional working capital, it would also allow Predictive Oncology to focus on the further development and commercialization of our two divisions focused on precision medicine.

The Company believes it will have updates on the future of its Skyline Medical business by early in 2020. The Company will evaluate its alternatives for the Skyline Medical business in order to maximize value for its stockholders. There is no assurance that the Company will ultimately receive offers for the division that it deems acceptable. Further, there is no assurance that the Company will enter into a definitive agreement or ultimately complete a sale of the division.

About Predictive Oncology Inc.

Predictive Oncology (POAI) operates through five segments (Domestic, International, Clinical, CRO and DCHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to its clients specific needs. Predictive Oncologys TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially fools cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis Oncology Capture Technology Platforms which isolate and help categorize an individual patients heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncologys Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit http://www.predictive-oncology.com.

Forward-looking Statements

Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Companys business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Companys and Helomics existing businesses, distraction of management and diversion of resources; and the market price of the Companys common stock may decline as a result of the merger; (ii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iii) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictives ability to implement its long range business plan for various applications of its technology; Predictives ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictives technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Companys reports filed with the SEC, which are available for review at http://www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictives financial position. See Predictives most recent Annual Report on Form 10-K, and subsequent reports and other filings at http://www.sec.gov.

Story continues

Read more here:
Predictive Oncology Confirms Indications of Interest for Skyline Medical Business - Yahoo Finance

The GenomeAsia 100K consortium analyzed the genomes of 1,739 people, which represents the widest coverage of genetic diversity in Asia to date.

The study covers 64 different countries and provides what the authors call the first comprehensive genetic map for Asia that will guide scientists in studying diseases unique to Asians, improve precision medicine and identify drugs that may carry higher risk of adverse reactions for certain ethnic groups.

Despite forming over 40 per cent of the worlds population, Asian people have previously accounted for only six per cent of the worlds recorded genome sequences.

The goal of GenomeAsia 100K, which launched in 2016, is to better understand the genome diversity of Asian ethnicities by sequencing 100,000 genomes of people living in Asia. It is a non-profit consortium hosted by Nanyang Technological University, Singapore (NTU Singapore), the only academic member. Its three other members are Macrogen based in South Korea, Genentech, a member of the Roche Group in United States, and MedGenome from India/US.

NTU Professor Stephan C. Schuster, the consortiums scientific chairman and a co-leader of the study, explained the significance of GenomeAsia 100Ks initial findings on the vast genomic diversity in Asia: To put it into context, imagine we looked at all people of European and based on the level of their genetic diversity, observed that they could all be grouped into just one ancestral lineage or population. Now, if we took that same approach with our new data from people of Asian, then based on the much higher levels of genetic diversity observed we would say that there are 10 different ancestral groups or lineages in Asia.

Schuster added, GenomeAsia 100K is a significant and far-reaching project that will affect the well-being and health of Asians worldwide, and it is a great honour for Singapore and NTU to be hosting it.

Executive Chairman of GenomeAsia 100K, Mahesh Pratapneni said, The publication of this pilot study is a first milestone for GenomeAsia 100K, which is an unprecedented collaboration between academia and industry leaders in the field of genomics. We are certain more partners will join GenomeAsia 100K to accelerate medical breakthroughs for people of Asian heritage.

Chairman and CEO of MedGenome, the largest genomics and molecular diagnostics provider in South Asia with facilities in the US, Singapore and across India, Sam Santhosh, said, "We are excited that over 1000 whole genome sequence data from the Indian sub-continent will now be available to researchers; this is an initial step in covering the underrepresented geographies."

Prof Jeong-Sun Seo, at Seoul National University Bundang Hospital Consortium scientific co-chair and Chairman of Macrogen, said, I hope this Asian-focused study serves as a stepping stone for the democratization of health care and precision medicine in Asia.

How the database of Asian genomes was formed

Over the course of the last three decades prior to the pilot project, thousands of blood and saliva samples have already been collected by scientists and anthropologists from donors across Asia in hopes that one day, a deeper analysis to gain insights into the Asian community can be done.

Of particular interest were participants from remote and isolated communities, who have long been the subjects of study by anthropologists but have not yet undergone genomic analysis, until the GenomeAsia 100K project was kickstarted.

The pilot study included 598 genomes from India, 156 from Malaysia, 152 from South Korea, 113 from Pakistan, 100 from Mongolia, 70 from China, 70 from Papua New Guinea, 68 from Indonesia, 52 from the Philippines, 35 from Japan, and 32 from Russia.

Genomic DNA extracted from the blood and saliva samples was then sequenced in laboratories of the four consortium members in the US, India, South Korea and Singapore. The digital sequencing data were subsequently sent to Singapore for processing and storage.

Singapore was selected by the consortium as the host, as the country offered good travel connections for collaborating scientists, strong supercomputing facilities to crunch the data, and the required cybersecurity standards in its data centre for handling sensitive genetic data.

The combined data was compiled and analyzed by NTU scientists, including Assistant Professor Hie Lim Kim, a population genomics expert at the Asian School of The Environment, with the help of the National Supercomputing Centre Singapore (NSCC) and international collaborators.

Different Asian ethnic groups respond differently to mainstream drugs

Every person has approximately 3.2 billion different nucleotides, or building blocks, in their genome, which form their DNA code.

Its estimated that for the genomes of any two people, 99.9 per cent of this code is the same and on average, 0.1 per cent or three million nucleotides, are different between them.

This genetic variance help humankind colonize the most diverse environments on the planet and make it resilient to disease, but it also results in differential response to many medicines.

Genetic variance is the reason we are distinctively different from each other including differences in the diseases that each of us suffer from during our lifetimes. Understanding these differences is the most important source of clues that we have for driving the discovery of innovative new medicines, said Dr Andrew Peterson, an author of the paper and an expert in the use of genetics to drive drug discovery.

Peterson was head of Molecular Biology at Genentech while this work was being carried out, is now Chief Scientific Officer at MedGenome, where he leads drug discovery efforts at MedGenomes Seven Rivers Genomic Medicines division.

The frequencies of known genetic variants related to adverse drug response were analyzed for the genomes collected in this study.

For example, warfarin, a common anticoagulant drug prescribed to treat cardiovascular diseases, likely has a higher than usual risk of adverse drug response for people carrying a certain genetic variant. This particular genetic variant has a higher frequency to appear in those with North Asian ancestry, such as Japanese, Korean, Mongolian or Chinese.

Using data analysis, scientists can now screen populations to identify groups that are more likely to have a negative predisposition to a specific drug.

Knowing a persons population group and their predisposition to drugs is extremely important if personalized medicine is to work, stressed Prof Schuster: For precision medicine to be precise, you need to know precisely who you are.

Hie Lim Kim, who leads the projects efforts in population genetics, added: Only by sequencing the entire genome of an individual can a persons ancestry and genetic background be known. Their genome explains why some people are afflicted by certain diseases while others arent. Scientists know that there is no single drug that works well for everybody and our latest findings not only reinforce this, but suggest how specific groups could be harmed by specific medicines.

Moving forward, the GenomeAsia 100K will continue to collect and analyze up to 100,000 genomes from all of Asias geographic regions, in order to fill in the gaps on the worlds genetic map and to account for Asias unexpected genetic diversity.

Reference

GenomeAsia100K Consortium. (2019) The GenomeAsia 100K Project enables genetic discoveries across Asia. Nature. DOI: https://doi.org/10.1038/s41586-019-1793-z

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See more here:
Insights into Asian Ancestry and Genetic Diversity - Technology Networks

BETHESDA, Md., Dec. 4, 2019 /PRNewswire/ --The American College of Medical Genetics and Genomics (ACMG) heads to a new destination in sunny San Antonio, Texas in 2020. Named one of the fastest growing meetings in the USA by Trade Show Executive Magazine, the ACMG Annual Clinical Genetics Meeting continues to provide groundbreaking research and news about the latest advances in genetics, genomics and personalized medicine. To be held March 17-21, the 2020 ACMG Annual Meeting will feature more than 40 scientific sessions, 3 Short Courses, workshops, TED-Style talks and satellite symposia, and over 800 poster presentations on emerging areas of genetic and genomic medicine.

Interview those at the forefront in medical genetics and genomics, connect in person with new sources and get story ideas on the clinical practice of genetics and genomics in healthcare today and for the future. Learn how genetics and genomics research is being integrated and applied into medical practice.

Topics include gene editing, cancer genetics, molecular genomics, exome sequencing, pre- and perinatal genetics, biochemical/metabolic genetics, genetic counseling, health services and implementation, legal and ethical issues, therapeutics and more.

Credentialed media representatives on assignment are invited to attend and cover the ACMG Annual Meeting on a complimentary basis. Contact Kathy Moran, MBA at kmoran@acmg.net for the Press Registration Invitation Code, which will be needed to register at http://www.acmgmeeting.net.

Abstracts of presentations will be available online in January 2020. A few 2020 ACMG Annual Meeting highlights include:

Program Highlights:

Cutting Edge Scientific Concurrent Sessions:

Three half-day Genetics Short Courses on Monday, March 16 and Tuesday, March 17:

Photo/TV Opportunity: The ACMG Foundation for Genetic and Genomic Medicine will present bicycles to local children with rare genetic diseases at the Annual ACMG Foundation Day of Caring on Friday, March 20 from 10:30 AM 11:00 AM at the Henry B. Gonzlez Convention Center.

Social Media for the 2020 ACMG Annual Meeting: As the ACMG Annual Meeting approaches, journalists can stay up to date on new sessions and information by following the ACMG social media pages on Facebook,Twitter and Instagram and by usingthe hashtag #ACMGMtg20 for meeting-related tweets and posts.

Note be sure to book your hotel reservations early.

The ACMG Annual Meeting website has extensive information at http://www.acmgmeeting.net.

About the American College of Medical Genetics and Genomics (ACMG) and the ACMG Foundation for Genetic and Genomic Medicine (ACMGF)

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical society dedicated to improving health through the clinical practice of medical genetics and genomics and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,300 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG peer-reviewed journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Kathy Moran, MBAkmoran@acmg.net

View original content to download multimedia:http://www.prnewswire.com/news-releases/press-registration-for-the-2020-acmg-annual-clinical-genetics-meeting-is-now-open-300969157.html

SOURCE American College of Medical Genetics and Genomics

Continue reading here:
Press Registration for the 2020 ACMG Annual Clinical Genetics Meeting Is Now Open - P&T Community

Not long after announcing a wide-ranging partnership with Microsoft to bring artificial intelligence tools to every desk across its R&D departments, Novartis is now teaming up with Amazons mammoth cloud computing division to overhaul its manufacturing, supply and business operations.

The new multiyear collaboration with Amazon Web Services dovetails with the drugmakers directives to embrace and incorporate digital technology at every point in its product pipeline and value chain.

AWS aims to supply the company with an enterprisewide data analytics platform, including AI and machine learning services, as well as cloud-based Insight Centers that will provide real-time metrics to Novartis global technical operations staff.

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

These centers will focus on tracking manufacturing lines and detecting bottlenecks as well as forecasting potential issues in quality and inventory. Novartis hopes this will allow for new, optimized production models, as the company looks to scale up its work in challenging-to-make personalized medicines such as Zolgensma and Kymriah.

Most recently, company opened a new cell and gene therapy manufacturing facility last week in Stein, Switzerland, providing a European base of operations for tailored therapies. Previously, Novartis had to rely on back-and-forth flights across the Atlantic to service patients on the continent, with its sole Kymriah-producing facility being located in New Jersey.

RELATED: Novartis to put AI on every employee's desk through Microsoft partnership

Novartis also plans to use AWS internet of things and computer vision offerings to help improve its manufacturing inspections, by digitally scanning images of sites and tracking individual items to spot for potential risks or delays.

There is a lot we can learn from the AWS team, and while manufacturing is a great starting place, were keen to also explore where else we can apply this technology, Novartis chief digital officer, Bertrand Bodson, said in a statement.

Using data science and digital technologies to reimagine the way we manufacture medicines is not only at the heart of our transformation, but also core to our ambition to bring innovative medicines to patients faster, Bodson added.

RELATED: Novartis' Sandoz goes digital from back office to 'not just apps,' therapeutics

Novartis currently operates more than 60 manufacturing sites worldwide, producing treatments used by nearly 1 billion people. Through its partnership with AWS, the drugmaker hopes to develop standard metrics for site efficiency, deliverable on a single dashboard illustrating global performance.

The company has already been using Amazons computer vision products to double-check that batch manufacturing lines are clear and cleaned after use, and prepared to begin their next scheduled set of tasks. Novartis is also employing AI to extract and analyze data from printed manufacturing documents.

The forthcoming site-based Insight Centers look to make these data available in real time to help avoid unnecessary inventory and machine downtime when producing small-batch and personalized treatments.

More:
Novartis' digital transformation continues apace with Amazon supply chain tie-up - FierceBiotech

LAGUNA HILLS, Calif., Dec. 5, 2019 /PRNewswire/ --Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced today the official appointment of David J. Dabbs, MD, a world renowned expert in breast pathology, to its medical team to provide pathology leadership for both currently marketed tests and services and others in development.

Dr. Dabbs joins PreludeDx with over 30 years of experience in direct patient care and clinical research at university-based pathology practices. He has educated hundreds of pathologists globally through his previous academic appointments including most recently as Professor and Chief of Pathology at Magee-Women's Hospital of UPMC, Pittsburgh, PA. He has ledpresentations at key international medical meetings and co-authored textbooks which have become the diagnostic standard in pathology, Breast PathologyandDiagnostic Immunohistochemistry (Elsevier, New York). Dr. Dabbs has advanced the field of breast pathology and the cancer community's understanding of ductal carcinoma in situ (DCIS) and breast cancer by publishing over 200 papers in peer-reviewed medical journals.

In addition to providing pathology guidance for the company's DCISionRTtest and future developments, Dr. Dabbs will lead Prelude's newly launched second opinion service, BREAST SOS, a consultation service designed for patients and the breast care team. "I am first and foremost a fierce patient advocate. My role with PreludeDx will be to help patients through the work we do today and by guiding the on-going development and validation of new approaches for women diagnosed with DCIS and early stage breast cancer," Dabbs said. "I believe precision medicine requires precision information. Both DCISionRT and BREAST SOS add clarification and needed information to help clinicians and patients make the right decisions about individual patient care."

Daniel Forche, President and CEO of PreludeDx, stated, "We are honored to have David join us to apply his mastery and experience in breast cancer diagnosis, biomarker development and patient care. His addition to the team further supports the principles upon which we were founded; Patient Focus, Quality First and Driving Innovation. Every patient should have access to an expert second opinion, and with Dr. Dabbs at the helm of BREAST SOS, we can help make this a reality for women around the world by providing expertise and clarification during their time of need."

About David J. Dabbs, MD

David J. Dabbs, MD is a thought leader in breast pathology. He has published over 200 papers and has several editorial board appointments and responsibility for peer review of pathology journals. He completed his medical degree at Medical College of Ohio, and his residency and fellowship at University of Washington and Affiliated Hospitals. Dr. Dabbs served as Director of Anatomic Pathology, and Chief of Pathology, Magee-Women's Hospital of UPMC, Pittsburgh, PA for over 15 years. Most recently, he was Professor of Pathology, University of Hawaii Cancer Center, John A. Burns School of Medicine. He is certified by the American Board of Pathology for Anatomic Pathology and Cytopathology.

About DCISionRT for Breast DCIS

DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. In the US, over 60,000 women are newly diagnosed with DCIS each year. The test was developed by PreludeDx and built on research that began with funding from the National Cancer Institute to better understand the biology of DCIS. DCISionRT assesses a woman's individual tumor biology along with other risk factors to provide a personalized recurrence risk. The test provides a Decision Scorethat identifies a woman's risk as low or elevated. DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.

About PreludeDx

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your Risk.

For more information on how PreludeDx is making a difference for patients, please visit the Company's website: http://www.preludedx.com

PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in the United States and foreign countries.

SOURCE PreludeDx

Home

Go here to read the rest:
PreludeDx Announces David J. Dabbs, MD as Chief of Pathology and Director of BREAST SOS (Second Opinion Service) - PRNewswire

Getting a blood draw is a standard first step toward almost any medical diagnosis whether your doctor is concerned that you are anemic, have kidney disease or diabetes, or as part of a standard screening during pregnancy. Most of these tests check for a shortage or excess of a particular factor (often a protein) in the blood, which acts as a clue for physicians about a potential health risk.

But what if instead of needing a different blood draw for each suspected health issue, doctors could order up a single blood test that would combine a hundred or more different measures to reveal a holistic portrait of your overall health as well as your risk for a whole host of diseases? Such a test could be administered widely to inform early individualized interventions designed to keep everyone healthy longer.

This is the dream of UC San Francisco physician Peter Ganz, M.D., and colleagues at Colorado-based SomaLogic Inc., who are developing what they call liquid health check technology a single blood test capable of painting a detailed portrait of a persons current health and future disease risks. The technology uses tiny fragments of DNA and RNA called aptamers that are able to identify and measure thousands of different circulating proteins from a small blood sample to reveal information about the health of organs across the body.

In a proof-of-concept study published Dec. 2, 2019, in Nature Medicine, researchers led by Ganz and scientists at SomaLogic and the University of Cambridge, measured the levels of 5,000 different proteins in archived blood plasma samples from nearly 17,000 individuals participating in five different longitudinal health studies. This yielded a total of 85 million protein measurements, making this the largest such study to date, the authors say.

Applying sophisticated machine learning computer algorithms to this massive data set revealed protein expression patterns that correlated with 11 different measures of patients overall health and their risk of developing certain diseases in the years following the initial blood draw. For example, the test could predict how much fat a persons liver contained (associated with liver cirrhosis as well as cardiovascular disease and insulin resistance), their overall level of physical fitness, or whether they later suffered a heart attack or developed diabetes.

We spoke with Ganz who is Maurice Eliaser Distinguished Professor of Medicine at UCSF and director of the Center of Excellence in Vascular Research at Zuckerberg San Francisco General Hospital and Trauma Center about the new study, and about his hopes for liquid health check technology to advance personalized precision medicine. (See the news release by Cambridge University for more details on the study.)

What is a liquid health check and what is your vision for the potential of this technology to improve patients health?

We coined the term liquid health check to refer to information about a persons risks of future diseases, current states of health and modifiable behaviors that can be discerned entirely from different patterns of proteins in blood.

Many people have used blood protein measurements to predict the risk of one disease at a time, but the idea of a liquid health check is to use protein scanning on a large scale to simultaneously predict the risk of numerous diseases and holistically identify an individuals state of health from head to toe.

The results of our studies show that scanning the levels of thousands of blood proteins can simultaneously capture the necessary information to deliver a one-stop test for personalized detection, prevention and treatment of many diseases. This would certainly be much more convenient and likely much less expensive than needing multiple rounds of clinical visits and tests to track down something thats going wrong in your body.

In our newest proof-of-concept study, we were able to predict 11 different kinds of health information about our participants, just by looking at proteins in their blood. Ultimately, our goal is to predict more than 100 diseases or states of health from a single blood sample, which would really be a new paradigm for a blood test.

Which types of health conditions are most amenable to evaluation through a blood test?

From all the studies conducted with blood protein scanning to date, there is evidence that protein patterns can pinpoint propensity for heart disease, diabetes, liver disease, kidney disease, cognitive brain impairment and cancer. We hope that we will ultimately find protein signatures for diseases that afflict most if not all human organs and tissues.

As a cardiologist, how did you get involved in the development of this technology?

I spent most of my career at Brigham and Womens Hospital in Boston as a cardiologist studying human endothelial biology. When I came to UCSF in 2008, I wanted to do something different, but didnt know what it would be. I was introduced to the chief medical officer of SomaLogic quite serendipitously, but I came out of that meeting with my eyes opened about the potential of the technology they were developing.

I have been on their Medical Advisory Board ever since I dont take any money from them or any other company and have basically helped to guide the development of clinical applications of their technology.

The ability to analyze blood proteins and link them to human disease is going to be a critical tool of the precision medicine revolution.Peter Ganz, M.D.

Initially we focused on cardiovascular applications, in part because of my background, and in 2016 we published a study in JAMA where we used the technology to predict the future risk of heart attacks, strokes, heart failure and death based on nine different blood proteins.

After that paper, we decided that with a technology that can measure 5,000 proteins simultaneously in a sample of blood, why underutilize this platform, measuring just nine proteins to inform cardiovascular outcomes? We talked about how we could take advantage of a platform that could measure so many different proteins, and thats how we arrived at the idea of developing liquid health checks a holistic approach to disease prevention and management that is not constrained by any one specialty.

How are you collaborating with SomaLogic to develop liquid health check technology? How have new technologies made this vision possible?

This project represents an exemplary collaboration between academic institutions and an industry partner. SomaLogic has developed a unique technology to quantify thousands of blood plasma proteins at once, while my academic colleagues and I have played a key role in linking blood protein patterns to propensity for developing illnesses or for maintaining good health in studies that have required participation of many thousands of patients worldwide.

The ability to analyze blood proteins and link them to human disease is going to be a critical tool of the precision medicine revolution. In fact, these protein scans are not just a fantasy in the distant future. A limited initial release version of the protein test is now available for clinical use.

One thing I think is very important for establishing confidence in this technology is that we are all dedicated to openness and transparency. From the get-go we agreed that everything thats learned will be published, and weve even pushed journals to publish hundreds of pages of supplementary materials to ensure that anyone who wants to can replicate our results.

Disclosures: Dr Ganzs proteomic research is supported by National Institutes of Health grants 1RO1HL129856, 1UO1DK108809, and 1R01AG052964. Dr. Ganz serves on the medical advisory board to SomaLogic Inc., for which he accepts no salary, honoraria, or any other financial incentives.

Read more here:
Toward a head-to-toe health check from a single blood test - University of California

Industrial conglomerate General Electric hosted an investor teach-in in Chicago at a medical conference on Monday. The company reviewed its health-care franchise in a post-biopharma world. GE is selling its biopharma business to Danaher for $21 billion. Now investors have to evaluate the growth and margin potential of what is left.

GE Healthcare is a large global medical device company, said division CFO Monish Patolawala at the event. $17 billion in revenue, midteen margins with strong free cash flow conversion, with good opportunity to continue organic growth and margin expansion while still delivering good free cash flow conversion.

GEs case for its division is health care is a good franchise with solid profitability and decent growth. Bearish analysts dont see it that way.

We come away from the GE Healthcare investor day with no change to our negative view, wrote J.P. Morgan analyst (and known GE bear) Stephen Tusa in a Tuesday research report. While we believe this is an OK asset that has some opportunity to be managed better, we were underwhelmed by [the] presentation.

In particular, Tusa believes low research and development spending is a problem for the division. That theme was picked up by another bearish analyst, Gordon Hasketts John Inch.

Siemens reps at the show expressed pride in the companys outsized R&D budget and new product development, wrote Inch, contrasting GEs R&D spending with its rival Siemens Healthineers (SHL.Germany). For instance, Siemens talked about Dual Source CT scanner which is a technology that Siemens invented years ago but that competitors are just introducing.

GE management pointed out that a larger portion of its health-care business is in servicesfixing the installed based of diagnostic products. That skews the R&D as a percentage of sales comparisons, according to the company.

RBC analyst Deane Dray likes the service business mix. We liked hearing that recurring revenues account for 45% of health cares mix, Dray wrote following the event. And leverage to ongoing trends such as digital [and artificial intelligence] solutions and demand for precision health, which helps tackle waste in the health care industry and improve the accuracy of diagnostics. GE management spent a lot of time laying out how computing power is helping health-care professionals save time and how new technologies create opportunities for personalized medicine.

Tusa and Inch both rate GE shares the equivalent of sell with $5 and $7 price targets, respectively. Dray, on the other hand, rates shares buy and has a $14 price target for the stock.

GEs Healthcare Investor day highlighted the companys diversified global health care portfolio, wrote Citigroup analyst Andrew Kaplowitz. He focused on the outlook for health care in his research report. Despite a lower organic growth [and operating profit] margin profile following the pending sale of BioPharma, [GE Healthcare] could remain well positioned to contribute to growth over time.

The biopharma business has higher margins than the rest of GE Healthcare, which sells large, heavy diagnostic equipment. Kaplowitz is another bull and rates GE shares the equivalent of Buy, with a $14 price target.

Credit Suisse analyst John Walsh sums up the divide between bulls and bears by taking a middle path. We think GE Healthcare management presented a credible growth plan that should be enhanced by margin expansion and greater [free cash flow generation], wrote Walsh, who rates shares Hold. He sees a decent franchise with upside for shareholders if management can improve profitability.

One thing GE management didnt address in Chicago was the potential for a future health-care initial public offering. That was the plan for the division before the biopharma units sale was announced. The $21 billion coming in from that sale eliminated the need to raise money by selling GE Healthcare shares to the public. Now analysts wonder if an IPO is still in the cards.

GE stock dropped Monday and is down again Tuesday, by about 2.7%. Any health-care disappointment or IPO uncertainty, however, isnt the likely culprit. More bad trade news has all industrial stocks lower. On Monday, President Donald Trump threatened tariffs on Brazil, Argentina, and France. Tuesday, he said he might wait until after the election to strike a trade deal with China.

For the year, GE shares are up about 50% year, far better than comparable gains of the S&P 500 index and Dow Jones Industrial Average over the same span.

Write to Al Root at allen.root@dowjones.com

See the original post:
GE Is Touting Its Health-Care Business, but It Isnt Helping the Stock - Barron's

Further Strengthens Business Development Team with Key Hire

PARSIPPANY, N.J., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences subsidiary, Interpace Pharma Solutions today announced that it is continuing to expand a previously announced partnership agreement to jointly develop, promote and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (Genecast) of the Peoples Republic of China (PRC). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the PRC. Interpace is sending members of its technical/scientific and business development teams to China this week to begin the tech transfer requirements to support over $3 million of recently secured new business with global pharmaceutical companies.

Michael McCartney, Chief Commercial Officer of Interpace Pharma Solutions commented, We will be joining the Genecast business development team in China to jointly promote our capabilities of tumor profiling testing and clinical testing services in China and will be traveling to Beijing, Suzhou and Shanghai to meet with Genecast pharma customers who are in need of Interpace Pharma Solutions services Mr. McCartney also added We are thrilled to announce the addition of Gordon Vansant, Ph.D. a highly regarded industry expert to our BD team. Dr. Vansant has deep relationships and contacts in China to further strengthen and expand our penetration in China and Asia and will lead our BD efforts in the Southwest US, headquartered out of San Diego.

Du Bo, Co-Founder and CEO of Genecast, said, We are excited that the partnership with Interpace Pharma Solutions is already working and we believe will strengthen our capabilities to provide our customers with high-quality, streamlined one-stop testing services globally. Interpace Pharma Solutions development is in line with our strategy of helping pharmaceutical and biotech companies on a global basis accelerate their biomarker-driven drug development and drive precision medicine forward.

Jack Stover, President & CEO of Interpace Biosciences commented, We are pleased with the new business already being booked as a result of our relationship with such a high-quality partner as Genecast and we are pleased to have such an experienced and successful executive as Dr. Vansant join our Pharma Solutions BD team. We look forward to expanding our partnership with Genecast as well as expanding our international capabilities in Europe, Asia and elsewhere in the near future, concluded Stover.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace Pharma Solutions is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP).

For more information, please visit Interpace Biosciences website atwww.interpace.com.

Genecast (Beijing) Biotechnology Co. Ltd.

Genecast is a leader in offering diagnostic products & services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the Peoples Republic of China (PRC). Genecasts laboratories have met all applicable standards for accreditation including accreditation from the CAP and earned top marks in a number of external quality assessments carried out by CAP, EMQN, the Clinical Test Center of the National Health Commission of China and Center of Clinical Laboratories of Shanghai.

Genecast has formed collaborations with more than 20 pharmaceutical and biotech companies in providing comprehensive pre-clinical and clinical testing services.

For more information, please visit Genecasts website at http://english.genecast.com.cn.

Media Contact:Dan ChenGenecast (Beijing) Biotechnologychen.dan@genecast.com.cn

Forward Looking Statements on Behalf of Interpace Biosciences

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other SEC filings. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

INTERPACE CONTACTS:Investor RelationsJoseph Green, Edison Groupjgreen@edisongroup.com

See more here:
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China - GlobeNewswire